|本期目录/Table of Contents|

[1]苏铭俊,张呈,容庭杰.CHOP 方案与FCD 方案治疗初治惰性淋巴瘤的疗效和安全性研究[J].慢性病学杂志,2016,(05):512-514.
　SU Ming-jun,ZHANG Cheng,RONG Ting-jie.Efficacy and safety of CHOP and FCD programmes on the initial treatment of indolent lymphoma[J].,2016,(05):512-514.
点击复制

CHOP 方案与FCD 方案治疗初治惰性淋巴瘤的疗效和安全性研究(PDF)

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
期数:
2016年05期
页码:
512-514
栏目:
论著
出版日期:
2016-07-26

文章信息/Info

Title:
Efficacy and safety of CHOP and FCD programmes on the initial treatment of indolent lymphoma
作者:
苏铭俊;  张呈;  容庭杰
江门市新会人民医院血液科，广东新会529100
Author(s):
SU Ming-jun;  ZHANG Cheng;  RONG Ting-jie
Department of Hematology, Xinhui People's Hospital, Xinhui, Guangdong 529100, China Corresponding author: SU Ming-jun, E-mail: SU731039@163.com
关键词:
初治惰性淋巴瘤; CHOP 方案; FCD 方案; 疗效; 安全性
Keywords:
Initial treatment of indolent lymphoma;  CHOP programme;  FCD programme;  Efficacy;  Safety
分类号:
R733.4
DOI:
-
摘要:
目的探讨环磷酰胺+多柔比星+长春新碱+泼尼松联合化疗(CHOP)方案和氟达拉滨+环磷酰胺+地塞 米松联合化疗(FCD)方案治疗初治惰性淋巴瘤的疗效和安全性。方法回顾性分析江门市新会人民医院 2012 年4 月—2015 年4 月入院的50 例行初治惰性淋巴瘤治疗的患者临床资料，按治疗方案的不同分为两 组，每组25 例。CHOP 组患者给予环磷酰胺+多柔比星+长春新碱+泼尼松联合化疗(CHOP 方案)，FCD 组 患者给予氟达拉滨+环磷酰胺+地塞米松联合化疗(FCD 方案)，比较两组患者治疗效果及骨髓抑制情况等。 组间率的比较采用χ2 检验。结果CHOP 组治疗后病情完全缓解(CR)5 例、部分缓解(PR)4 例、稳定(SD)8 例、进展(PD)5 例，有效率36.00%(9/25）；对照组分别为2、3、8、8 例和20.00%(5/25)，差异无统计学意 义（P>0.05）。CHOP 组患者骨髓抑制Ⅲ~Ⅳ度情况及骨髓总抑制情况均低于FCD 组患者，差异有统计学 意义（P＜0.01）。结论CHOP 方案与FCD 方案对初治惰性淋巴瘤的治疗效果无显著性差异，但FCD 组 患者骨髓抑制情况明显增强。
Abstract:
Objective To investigate the efficacy and safety of CHOP and FCD programmes in the treatment of newly diagnosed indolent lymphoma. Method A total of 50 patients with initial treatment of indolent lymphoma in Xinhui People’s Hospital from April 2012 to April 2015 were retrospectively analyzed. They were divided into two groups of 25 patients each. CHOP group were treated with combined chemotherapy of cyclophosphamide, doxorubicin, vincristine and prednisone. FCD group were treated with combined chemotherapy of fludarabine, cyclophosphamide, dexamethasone. Efficacy and myelotoxicity between the two groups were compared with chi- square test. Results After treatment of CHOP, 5 patients were complete remission (CR); 4 patients were partial remission (PR); 8 patients were stable (SD); 5 patients were progress (PD). The effective rate in the CHOP group was 36.0%. After treatment of FCD, there were 2 patients with CR; 3 patients with PR; 8 patients with SD; 8 patients with PD. The effective rate in the FCD group was 20.0% which wasn’t significantly different with that in the CHOP group (P>0.05). The incidence rates of Ⅲ-Ⅳ degree and total myelotoxicity in the CHOP group were all significantly lower than those in the FCD group (P<0.01). Conclusions There was no significant difference between CHOP programme and FCD programme on the initial treatment of indolent lymphoma, but bone marrow suppression of FCD is more obvious.

参考文献/References:

[1] 王晶石,崔华,黄达永,等.CHOP 方案与FCD 方案治疗初治惰 性淋巴瘤疗效分析[J]. 临床和实验医学杂志,2015,14(14): 1193-1195.
[2] 孙顺,黄新刚,陈桦.B 细胞惰性淋巴瘤患者外周血SHP-1 基因 甲基化检测及其意义[J]. 山东医药,2015,55(26):52-54.
[3] Steurer M. ASH update 2011: chronic lymphocytic leukemia and indolent lymphoma [J]. Magazine Eur Medi Oncol, 2012,5 (3):178-181.
[4] 章艳茹,邹德慧,邱录贵.造血干细胞移植在惰性淋巴瘤中的临 床应用研究进展[J]. 国际输血及血液学杂志,2011,34(6):541- 545.
[5] 陈磊.解毒散结合剂联合CHOP 化疗方案治疗恶性淋巴瘤随机 平行对照研究[J]. 实用中医内科杂志,2015,39(9):142-144.
[6] 徐笑笑,阎蓓,王振兴,等.氟达拉滨为主的联合方案与CHOP 样方案治疗初治惰性淋巴瘤的比较分析[J]. 中华血液学杂志, 2013,34(10):900-903.
[7] Blasé PE, Pasker-de Jong PCM, Hagenbeek A, et al. Predic? tive potential of FDG- PET/CT for histological transforma? tion in patients with indole

备注/Memo

备注/Memo:
作者简介：苏铭俊，大学本科，副主任医师，研究方向：血液淋巴瘤、多发性骨髓瘤等血液学方向 通信作者：苏铭俊，E-mail: SU731039@163.com
更新日期/Last Update: 2016-07-27